Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255892 | SCV000321641 | pathogenic | not provided | 2015-04-07 | criteria provided, single submitter | clinical testing | The c.668_669delAA variant in the FH gene causes a frameshift starting with codon Lysine 223, changes this amino acid to a Arginine residue and creates a premature Stop codon at position 26 of the new reading frame, denoted p.Lys223ArgfsX26. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Although this variant has not been previously reported to our knowledge, we interpret it to be pathogenic. |
Invitae | RCV000255892 | SCV001398443 | pathogenic | not provided | 2023-12-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys223Argfs*26) in the FH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FH are known to be pathogenic (PMID: 11865300, 21398687). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FH-related conditions. ClinVar contains an entry for this variant (Variation ID: 265147). For these reasons, this variant has been classified as Pathogenic. |
Myriad Genetics, |
RCV003456041 | SCV004187897 | pathogenic | Hereditary leiomyomatosis and renal cell cancer | 2023-07-05 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |
Baylor Genetics | RCV003469195 | SCV004197334 | likely pathogenic | Fumarase deficiency | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000255892 | SCV004225709 | likely pathogenic | not provided | 2022-09-30 | criteria provided, single submitter | clinical testing | PM2, PVS1 |